AnaptysBio (ANAB) Competitors $34.29 +2.44 (+7.66%) Closing price 04:00 PM EasternExtended Trading$34.22 -0.06 (-0.19%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB vs. NAMS, VKTX, AMRX, CNTA, XENE, CGON, QURE, RARE, APLS, and IMVTShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Amneal Pharmaceuticals (AMRX), Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), uniQure (QURE), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. Its Competitors NewAmsterdam Pharma Viking Therapeutics Amneal Pharmaceuticals Centessa Pharmaceuticals Xenon Pharmaceuticals CG Oncology uniQure Ultragenyx Pharmaceutical Apellis Pharmaceuticals Immunovant AnaptysBio (NASDAQ:ANAB) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability. Do analysts recommend ANAB or NAMS? AnaptysBio currently has a consensus target price of $54.78, indicating a potential upside of 59.75%. NewAmsterdam Pharma has a consensus target price of $42.00, indicating a potential upside of 3.83%. Given AnaptysBio's higher possible upside, equities research analysts plainly believe AnaptysBio is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.67NewAmsterdam Pharma 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Does the media prefer ANAB or NAMS? In the previous week, AnaptysBio had 9 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 16 mentions for AnaptysBio and 7 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.55 beat AnaptysBio's score of 0.52 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ANAB or NAMS? AnaptysBio has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Is ANAB or NAMS more profitable? AnaptysBio has a net margin of -107.66% compared to NewAmsterdam Pharma's net margin of -259.07%. NewAmsterdam Pharma's return on equity of -27.27% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-107.66% -366.98% -30.58% NewAmsterdam Pharma -259.07%-27.27%-25.00% Do institutionals and insiders believe in ANAB or NAMS? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 33.5% of AnaptysBio shares are held by company insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable valuation & earnings, ANAB or NAMS? AnaptysBio has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M10.52-$145.23M-$4.48-7.65NewAmsterdam Pharma$45.56M100.00-$241.60M-$1.62-24.97 SummaryNewAmsterdam Pharma beats AnaptysBio on 9 of the 17 factors compared between the two stocks. Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$891.70M$3.38B$6.11B$10.47BDividend YieldN/A2.29%5.73%4.77%P/E Ratio-7.6522.7785.3627.36Price / Sales10.52483.07607.44135.43Price / CashN/A46.7037.4661.86Price / Book14.7210.5512.426.81Net Income-$145.23M-$52.58M$3.32B$276.80M7 Day Performance7.73%1.09%1.01%0.27%1 Month Performance70.09%16.09%10.75%8.31%1 Year Performance3.07%18.41%76.20%35.60% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio2.6382 of 5 stars$34.29+7.7%$54.78+59.7%-8.3%$891.70M$91.28M-7.65100Analyst ForecastNAMSNewAmsterdam Pharma1.5633 of 5 stars$32.48+5.9%$42.00+29.3%+97.6%$3.45B$45.56M-20.054High Trading VolumeVKTXViking Therapeutics3.9661 of 5 stars$32.28+8.6%$86.42+167.7%-49.8%$3.34BN/A-21.1020Upcoming EarningsAMRXAmneal Pharmaceuticals3.8611 of 5 stars$10.55+1.5%$12.00+13.7%+12.2%$3.26B$2.85B1,056.068,100CNTACentessa Pharmaceuticals2.848 of 5 stars$23.00-1.0%$32.38+40.8%+34.5%$3.11B$6.85M-12.85200XENEXenon Pharmaceuticals2.686 of 5 stars$39.55-0.2%$53.30+34.8%-2.8%$3.05B$9.43M-11.14210Analyst ForecastCGONCG Oncology2.1752 of 5 stars$38.13-4.2%$56.55+48.3%+14.2%$3.04B$1.14M-21.5461QUREuniQure3.173 of 5 stars$52.91-3.7%$71.75+35.6%+945.4%$3.01B$27.12M-13.50500RAREUltragenyx Pharmaceutical4.4465 of 5 stars$30.19-3.3%$81.50+170.0%-43.6%$3.01B$610.16M-5.461,294News CoverageInsider TradeAnalyst RevisionAPLSApellis Pharmaceuticals4.1952 of 5 stars$24.36+2.4%$33.29+36.7%-15.4%$3.01B$781.37M-13.38770News CoverageAnalyst ForecastAnalyst RevisionIMVTImmunovant2.1245 of 5 stars$16.55-2.1%$33.20+100.6%-40.6%$2.95BN/A-5.81120News CoverageAnalyst Forecast Related Companies and Tools Related Companies NewAmsterdam Pharma Competitors Viking Therapeutics Competitors Amneal Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors CG Oncology Competitors uniQure Competitors Ultragenyx Pharmaceutical Competitors Apellis Pharmaceuticals Competitors Immunovant Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANAB) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
